Millipore Sigma Vibrant Logo
Atención: Nos hemos mudado. Los productos Merck Millipore ya no pueden adquirirse en MerckMillipore.comMás información

504842 CGP 37849 - CAS 127910-31-0 - Calbiochem

CGP 37849 - CAS 127910-31-0 - Calbiochem: Ficha de datos de seguridad (MSDS o SDS), certificado de análisis y de calidad (CoA y CoQ), expedientes, folletos y otros documentos disponibles.

Sinónimos: (E)-(±)-2-Amino-4-methyl-5-phosphono­-3-pentenoic acid

Primary Target: NMDA receptors
504842
Purchase on Sigma-Aldrich

Descripción

Replacement Information

Tabla espec. clave

CAS #Empirical Formula
127910-31-0C₆H₁₂NO₅P

Products

Número de referenciaEmbalaje Cant./Env.
5048420001 Frasco de vidrio 10 mg
Description
OverviewA highly potent competitive antagonist selective for NMDA receptors (Ki = 35 nM). Biologically viable admitted orally or systematically. Widely used in studies of epilepsy, schizophrenia, depression, stress and anxiety related mental disorders.
Catalogue Number504842
Brand Family Calbiochem®
Synonyms(E)-(±)-2-Amino-4-methyl-5-phosphono­-3-pentenoic acid
References
ReferencesSerafini, G., et al. 2013. Curr. Pharmaceut. Design 19, 1898.
Szewczyk, B., et al. 2012. Expert. Op. Invest. Drugs 21, 91.
Przegalinski, E., et al. 2000. Neuropharmacol. 39, 1858.
Maj, J., et al. 1993. Polish J. Pharmacol. 45, 455.
Fagg, E., et al. 1990. Br. J. Pharmacol. 99, 791.
Schmutz, M., et al. 1990. Naunyn-Schmiedebergʹs Arch. Pharmacol. 342, 61.
Product Information
CAS number127910-31-0
FormWhite solid
Hill FormulaC₆H₁₂NO₅P
Chemical formulaC₆H₁₂NO₅P
Structure formula ImageStructure formula Image
Quality LevelMQ100
Applications
Biological Information
Primary TargetNMDA receptors
Primary Target K<sub>i</sub>35 nM
Purity≥99% by Chiral HPLC
Physicochemical Information
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
Safety Information
Product Usage Statements
Storage and Shipping Information
Ship Code Shipped at Ambient Temperature or with Blue Ice or with Dry Ice
Toxicity Standard Handling
Storage +2°C to +8°C
Protect from Light Protect from light
Do not freeze Ok to freeze
Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Packaging Information
Transport Information
Supplemental Information
Specifications
Global Trade Item Number
Número de referencia GTIN
5048420001 04055977243598

Documentation

CGP 37849 - CAS 127910-31-0 - Calbiochem Ficha datos de seguridad (MSDS)

Título

Ficha técnica de seguridad del material (MSDS) 

Referencias bibliográficas

Visión general referencias
Serafini, G., et al. 2013. Curr. Pharmaceut. Design 19, 1898.
Szewczyk, B., et al. 2012. Expert. Op. Invest. Drugs 21, 91.
Przegalinski, E., et al. 2000. Neuropharmacol. 39, 1858.
Maj, J., et al. 1993. Polish J. Pharmacol. 45, 455.
Fagg, E., et al. 1990. Br. J. Pharmacol. 99, 791.
Schmutz, M., et al. 1990. Naunyn-Schmiedebergʹs Arch. Pharmacol. 342, 61.
Ficha técnica

Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

Revision17-July-2013 JSW
Synonyms(E)-(±)-2-Amino-4-methyl-5-phosphono­-3-pentenoic acid
DescriptionA highly potent competitive antagonist selective for NMDA receptors (Ki = 35 nM). Biologically viable admitted orally or systematically. Widely used in studies of epilepsy, schizophrenia, depression, stress and anxiety related mental disorders.
FormWhite solid
CAS number127910-31-0
Chemical formulaC₆H₁₂NO₅P
Structure formulaStructure formula
Purity≥99% by Chiral HPLC
SolubilityH₂O (100 mM). Slight warming is required for complete solubilization.
Storage Protect from light
+2°C to +8°C
Do Not Freeze Ok to freeze
Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Toxicity Standard Handling
ReferencesSerafini, G., et al. 2013. Curr. Pharmaceut. Design 19, 1898.
Szewczyk, B., et al. 2012. Expert. Op. Invest. Drugs 21, 91.
Przegalinski, E., et al. 2000. Neuropharmacol. 39, 1858.
Maj, J., et al. 1993. Polish J. Pharmacol. 45, 455.
Fagg, E., et al. 1990. Br. J. Pharmacol. 99, 791.
Schmutz, M., et al. 1990. Naunyn-Schmiedebergʹs Arch. Pharmacol. 342, 61.